Energesis Pharmaceuticals
Energesis Pharmaceuticals is dedicated to developing novel therapeutics for sustainable weight loss in patients with obesity. Their approach focuses on increasing energy expenditure through brown adipose tissue (BAT) recruitment, aiming to address unmet needs in obesity treatment with a safe, effective, and potentially oral solution. The company combines scientific innovation with entrepreneurial expertise to develop a new class of agents to effectively cure obesity.
Industries
Nr. of Employees
small (1-50)
Energesis Pharmaceuticals
Cambridge, Massachusetts, United States, North America
Patents
Methods and compositions for inducing differentiation of human brown adipocyte progenitors
US-11419916-B2
View DetailsBrown adipocyte progenitors in human skeletal muscle and methods for identifying differentiation agents therefor
US-8455204-B2
View Details
Methods and compositions for inducing differentiation of human brown adipocyte progenitors
US-11419916-B2
View DetailsBrown adipocyte progenitors in human skeletal muscle and methods for identifying differentiation agents therefor
US-8455204-B2
View DetailsProducts
Oral small-molecule BAT-recruiting therapeutic candidates (pipeline)
Orally administered small-molecule candidates designed to recruit brown adipose tissue and increase energy expenditure to induce fat-specific weight loss while preserving lean mass.
EGS-2632
An orally bioavailable combination of two safe, previously-marketed drugs that increases human brown adipocyte mass, producing robust weight loss from fat and synergistic efficacy with GLP-1 agonists without rebound weight gain.
Oral small-molecule BAT-recruiting therapeutic candidates (pipeline)
Orally administered small-molecule candidates designed to recruit brown adipose tissue and increase energy expenditure to induce fat-specific weight loss while preserving lean mass.
EGS-2632
An orally bioavailable combination of two safe, previously-marketed drugs that increases human brown adipocyte mass, producing robust weight loss from fat and synergistic efficacy with GLP-1 agonists without rebound weight gain.
Expertise Areas
- Obesity therapeutics development
- Brown adipose tissue biology and recruitment
- Small-molecule drug discovery
- Translational imaging (PET/CT) for metabolic endpoints
Key Technologies
- Brown adipose tissue recruitment/activation
- Small-molecule therapeutics
- Oral drug formulation
- PET/CT imaging for BAT